Hepatitis Forums

Hepatitis B Main Forums => Hepatitis B => Topic started by: Hep Editors on January 17, 2019, 10:32:41 am

Title: For Recipients of Hep B–Infected Liver Transplants, Vemlidy Is Less Toxic
Post by: Hep Editors on January 17, 2019, 10:32:41 am
People who receive hepatitis B virus (HBV)­–infected liver transplants have better indicators of kidney and bone health after one year of Vemlidy (tenofovir alafenamide, or TAF) prophylaxis treatment compared with taking Viread (tenofovir disoproxil fumarate, or TDF).

Presenting their findings at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco (The Liver Meeting), researchers conducted a Phase II open-label study (meaning participants knew which drug they were receiving) in New Zealand including 51 liver transplant recipients taking Viread as HBV prophylaxis treatment.